Nervgen Pharma Corp (NGEN) Stock Price, Quote & News

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology

Sector: Healthcare

Phone: 778-731-1711

Website: www.nervgen.com

Address:

112-970 Burrard Street, Unit 1290, Vancouver, Canada

ReggieTrades Apr. 30 at 12:55 AM

$NGEN Some Reddit discussions piqued my curiosity about something: Have they mentioned the use of a data observer to possibly help make the case for accelerated approval? If an IDMC reports strong evidence of recovery at some point during the trial, I would imagine that it would be a major boost towards early approval.

0 · Reply

aladdinscarpet Apr. 29 at 6:29 PM

$NGEN adding. We don’t need no stinkin’ oil, and the world won’t be held hostage to narcissistic fever dreams much longer. The US has fulfilled the prophecy of HL Mencken.

1 · Reply

alexandredaigneault96 Apr. 29 at 6:23 PM

$NGEN wtf !!!! Down again .

0 · Reply

KY3000 Apr. 29 at 6:16 PM

$NGEN max pain coming, cfo gotta go to work

0 · Reply

Eldorado_Toole Apr. 29 at 6:12 PM

$NGEN Buying at 3.66

0 · Reply

KvoGicho Apr. 29 at 5:34 PM

$NGEN company has a history of pushing the price down for financings and options...... wondering if this is why we have had constant selling into volume?

1 · Reply

KY3000 Apr. 29 at 4:59 PM

$NGEN cfo should help with the cash, I’m watching for the filings

0 · Reply

TH3_PR0F1T Apr. 29 at 12:13 PM

$NGEN Biopharma Advances High-Impact First-of-Its-Kind Neuroreparative Drug https://share.google/etXIVCEQm7T5Aam7R

2 · Reply

NextGener Apr. 29 at 12:34 AM

$NGEN In the full year 2025 financial results and business update the following was stated "Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026." What type of regulatory update would they be providing? More information on what was discussed at the EOP2 meeting? They've agreed to the phase 3 design, what more information is typically released from these meetings? An agreement on an accelerated approval pathway perhaps?

2 · Reply

PETESHICK Apr. 28 at 4:22 PM

$NGEN if only this were accurate… https://www.instagram.com/reel/DXpQ4MtEd0b/?igsh=MWk5ajU2aXB5bDU5MQ==

0 · Reply

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

Apr 13, 2026, 7:45 AM EDT - 16 days ago

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 7, 2026, 7:30 AM EDT - 22 days ago

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Mar 31, 2026, 7:45 AM EDT - 4 weeks ago

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Mar 12, 2026, 4:15 PM EDT - 6 weeks ago

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Mar 4, 2026, 7:30 AM EST - 2 months ago

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

Feb 18, 2026, 7:30 AM EST - 2 months ago

NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 12, 2026, 4:15 PM EST - 2 months ago

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

Feb 11, 2026, 7:00 AM EST - 2 months ago

NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium

Feb 9, 2026, 7:00 AM EST - 2 months ago

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Jan 8, 2026, 6:30 AM EST - 3 months ago

NervGen Pharma Begins Trading on Nasdaq Today

Dec 17, 2025, 4:18 PM EST - 4 months ago

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Dec 12, 2025, 7:51 PM EST - 4 months ago

NervGen Pharma Announces Proposed Amendment to Warrants

Nov 24, 2025, 7:05 AM EST - 5 months ago

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Nov 24, 2025, 7:00 AM EST - 5 months ago

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Nov 19, 2025, 4:26 PM EST - 5 months ago

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Nov 18, 2025, 4:42 PM EST - 5 months ago

NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Aug 26, 2025, 7:30 AM EDT - 8 months ago

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Aug 21, 2025, 7:30 AM EDT - 8 months ago

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Jul 17, 2025, 7:30 AM EDT - 10 months ago

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Jul 7, 2025, 5:30 PM EDT - 10 months ago

NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update

Jul 3, 2025, 4:41 PM EDT - 10 months ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Jul 1, 2025, 7:30 AM EDT - 10 months ago

NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones

Jun 18, 2025, 7:30 AM EDT - 11 months ago

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role

May 21, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting

May 16, 2025, 4:30 PM EDT - 1 year ago

NervGen Pharma Grants Stock Options

May 15, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

May 7, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Apr 21, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2025, 5:53 PM EDT - 1 year ago

NervGen Provides Quarterly "At-The-Market" Equity Program Update

Apr 3, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event

Mar 5, 2025, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Virtual Life Science Investor Forum

Feb 6, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Jan 29, 2025, 5:00 PM EST - 1 year ago

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 2, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program

Nov 14, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Nov 7, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Sep 20, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Sep 16, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Aug 27, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 22, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Aug 6, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Jul 22, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Appoints Neil Klompas to Board of Directors

Jun 25, 2024, 8:30 AM EDT - 2 years ago

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

Jun 20, 2024, 8:30 AM EDT - 2 years ago

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

May 17, 2024, 8:30 AM EDT - 2 years ago

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

ReggieTrades Apr. 30 at 12:55 AM

0 · Reply

aladdinscarpet Apr. 29 at 6:29 PM

$NGEN adding. We don’t need no stinkin’ oil, and the world won’t be held hostage to narcissistic fever dreams much longer. The US has fulfilled the prophecy of HL Mencken.

1 · Reply

alexandredaigneault96 Apr. 29 at 6:23 PM

$NGEN wtf !!!! Down again .

0 · Reply

KY3000 Apr. 29 at 6:16 PM

$NGEN max pain coming, cfo gotta go to work

0 · Reply

Eldorado_Toole Apr. 29 at 6:12 PM

$NGEN Buying at 3.66

0 · Reply

KvoGicho Apr. 29 at 5:34 PM

$NGEN company has a history of pushing the price down for financings and options...... wondering if this is why we have had constant selling into volume?

1 · Reply

KY3000 Apr. 29 at 4:59 PM

$NGEN cfo should help with the cash, I’m watching for the filings

0 · Reply

TH3_PR0F1T Apr. 29 at 12:13 PM

$NGEN Biopharma Advances High-Impact First-of-Its-Kind Neuroreparative Drug https://share.google/etXIVCEQm7T5Aam7R

2 · Reply

NextGener Apr. 29 at 12:34 AM

2 · Reply

PETESHICK Apr. 28 at 4:22 PM

$NGEN if only this were accurate… https://www.instagram.com/reel/DXpQ4MtEd0b/?igsh=MWk5ajU2aXB5bDU5MQ==

0 · Reply

MarianoItaliano Apr. 28 at 1:33 PM

$QQQ $SPY $XBI $IBB I understand that we're living in exciting times of ai slop, conquering empty space and pre-programmed robots doing dancing, flips and other party tricks but is it really that exciting to a point where wall street completely ignores revolution which is happening in biotech world? $NGEN is trying to bring to the market a peptide which makes paralyzed people walking again and the market simply doesn't care, smh. https://vimeo.com/1139656943/8028c1f465

3 · Reply

TH3_PR0F1T Apr. 28 at 1:20 PM

$NGEN H.C. Wainwright reiterates NervGen stock rating on new CFO hire By Investing.com https://share.google/tQTnuFnGfef11KTqL

0 · Reply

helloitisme Apr. 28 at 11:18 AM

$NGEN love this company. But I'm struggling to get my buy orders filled. Even small amounts

0 · Reply

focafoca99 Apr. 28 at 5:43 AM

$NGEN appointed Keith Vendola as chief financial officer effective immediately.

0 · Reply

MarianoItaliano Apr. 27 at 9:56 PM

$NGEN $XBI One thing I don't understand is that despite so much coverage by the media (CNBC, Fox News), compelling story, listing on NASDAQ, known names on board (John Ruffolo, Rich Macary, Mike Kelly (ex CEO)) we still are not growing observers on stocktwits. This tells me that somehow we're flying under the radar even though every time any analyst takes a look at the company they evaluate it 3-5x current price. I'm not saying that the current management is doing a bad job but it looks like nowadays it's still not enough. I guess we've gotta spread the message by ourselves. If you're really into biotech you should at least observe it imo. https://vimeo.com/1078062513 https://www.youtube.com/watch?v=XwRDl0AYZrQ https://www.youtube.com/watch?v=Ynxu-hyCLxg https://www.youtube.com/watch?v=QQrzxiYbJkw https://www.youtube.com/watch?v=H_MpLIIXQ9g

2 · Reply

TH3_PR0F1T Apr. 27 at 8:17 PM

$NGEN Nothing like positive news to move the share price!🤣

1 · Reply

Witzorwitzout1 Apr. 27 at 4:55 PM

$NGEN california has a fund for bios. Carney announces creation of Canadian sovereign wealth fund | AP News https://share.google/HZM1JrBQG7PBsHkei

0 · Reply

Tarquinjones Apr. 27 at 4:42 PM

$NGEN Ha

1 · Reply

aladdinscarpet Apr. 27 at 1:20 PM

$NGEN https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/52058957/this-lb-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday

0 · Reply

Gabriel_DS Apr. 27 at 11:54 AM

$NGEN https://finance.yahoo.com/sectors/healthcare/articles/nervgen-pharma-strengthens-leadership-team-113000691.html

0 · Reply

aladdinscarpet Apr. 27 at 5:29 AM

$NGEN https://youtu.be/U_RI5ncY3zQ

5 · Reply

PETESHICK Apr. 26 at 10:42 AM

$NGEN https://youtube.com/shorts/3OUrr_2UCYs?si=behXGI4d_E8TgylF

1 · Reply

Market Cap	N/A
Revenue (ttm)	46.92M
Net Income (ttm)	-38.10M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	0.00
Profit Margin	-81.20%
Debt to Equity Ratio	N/A

Volume	775,700
Avg Vol	145,364
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	80%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A